Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARTEMIS: Ravulizumab to prevent CSA-AKI and MAKE after cardiac surgery in CKD
jRCT2031230020Phase 3Active, not recruiting
- Sponsor
- Alexion Pharmaceuticals
- Start
- Apr 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in acute kidney failure (AKF), chronic kidney disease (CKD) and cardiac disease comparing Ravulizumab with Placebo (2 arms). Primary endpoint: Major Adverse Kidney Events (MAKE) based on serum cystatin C at Day 90 post-CPB. Started Apr 2023; status: active, not recruiting.
02
Drugs
ravulizumab
03
Conditions
acute kidney failure (AKF)chronic kidney disease (CKD)cardiac disease
Beyond the preview
Go deeper on jRCT2031230020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230020.